



PRESS RELEASE

Lelystad, April 23, 2010

FORNIX IS DISCUSSING SALE OF ITS ALLERGY DIVISION

Fornix BioSciences N.V. (Fornix) announces that it is in an advanced stage of a controlled auction process regarding the possible sale of its Allergy Division. Fornix expects to finalise this procedure on a short notice.

The materially altered circumstances regarding the registration status of Oralgen® Grasses, the announced restrictions by the government regarding the admission of allergen products and the discussions surrounding the reimbursement system, has caused Fornix to evaluate its available options for the Fornix group as a whole as well as for the Allergy Division and the Medical Aids Division individually. The Allergy Division is a substantial part of Fornix. For the financial year 2009, the allergy business represented 68% of the turnover and 83% of the EBIT.

No further announcements can be made by Fornix regarding the controlled auction. If agreement is reached on the sale of the Allergy Division, such transaction shall be submitted for approval to an Extra-ordinary Meeting of Shareholders.

END OF PRESS RELEASE

For more information, please contact:

**Fornix BioSciences N.V.
Mr C.L. Bergman, CEO
Tel. (0320) 26 77 99
Website: www.fornix.nl**

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam: AFORBI) which engages mainly in the development and sale of diagnostic and therapeutic allergen products and the distribution of medical aids and medical and nursing consumables.

Fornix BioSciences N.V. has sites in Lelystad, Beuningen and Hamburg. The company currently has 138 employees and operates mainly in the Netherlands and Germany. Its activities are conducted by two divisions, the Allergy Division consisting of Artu Biologicals Europe and the Medical Aids Division. The activities of Artu Biologicals Deutschland are conducted separately from these two divisions.

The Allergy Division focuses on the development, production and sale of a wide range of patient-friendly immunotherapeutic products including the Oralgen[®] and Igevac[®] brands. These products are administered in the causal treatment of allergies triggered by various allergens, such as grass and tree pollen and house-dust mites. The development programme is supported by high-quality R&D activities and pan-European clinical studies on the effectiveness and safety of the various products. Clinical research should over time lead to the registration of the company's most important allergen products Oralgen[®] Grass Pollen, Tree Pollen and House-dust mite. In the coming years, the company intends to increase its focus on allergen products and to expand its position in the growing immunotherapy market in Europe.

Artu Biologicals Deutschland in Hamburg carries a growing range of medical aids in Germany on an exclusive basis. The Oralgen[®] equivalent Igevac[®] is also distributed in this market on a named-patient basis.

The Medical Aids Division consists of Laprolan, located in Beuningen. The division focuses on the sale, marketing and distribution of a wide range of medical aids and medical and nursing consumables.
